Log in  First Connection?
  
EnglishJapaneseFrenchSpanishGerman

Others Urological ConditionsArchives

Comparing the clinical accuracy of urine exfoliated cell examination and fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma
Others Urological Conditions
 4 min.

 Published on 12/06/2026 |  Original article (Full-text)  | Wang Chundan et al. | BMC Urology 2025; 26(1): 32

Upper urinary tract urothelial carcinoma (UTUC), which refers to renal pelvis cancer and ureteral cancer, is a rare malignant tumor that comprises 5% to 10% of all urothelial tumors. Based on statistics, UTUC has an incidence of approximately 2/100,000, or 2 per 100,000 of the general population [1,...

HTML version PDF version  Print abstract

Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing
Others Urological Conditions
 1 min.

 Published on 05/06/2026 |  Original article (Full-text)  | Abdul Rahman Al Armashi et al. | Expert Review of Anticancer Therapy 2026; aop:10.1080/14737140.2026.2628071

Managing urothelial carcinoma with immune checkpoint inhibitors requires addressing issues beyond clinical outcomes. Implementation difficulties affect most patients, predictive biomarkers show limited utility, and treatment discontinuation from toxicity remains problematic. This article integrates clinical...

HTML version PDF version  Print abstract

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma
Others Urological Conditions
 1 min.

 Published on 29/05/2026 |  Original article (Full-text)  | Matthew D. Galsky et al. | Future Oncology 2026; 22(12): 1387-1396

Enfortumab vedotin (EV) plus pembrolizumab is the first-line standard of care for patients with locally advanced or metastatic urothelial carcinoma (la/mUC). However, randomized data to guide treatment after progression on EV plus pembrolizumab are limited. Datopotamab deruxtecan (Dato-DXd), a trophoblast...

HTML version PDF version  Print abstract

Real-world treatment patterns for metastatic urothelial cancer in 5 European countries: EVEREST 2
Others Urological Conditions
 1 min.

 Published on 22/05/2026 |  Original article (Full-text)  | Maria De Santis et al. | Future Oncology 2026; 22(12): 1429-1437

Treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) is evolving in Europe. In 2022, ESMO guidelines recommended avelumab as first-line (1L) maintenance for la/mUC in patients who did not progress on platinum-based chemotherapy (PBC) and, in March 2024, recommended enfortumab vedotin...

HTML version PDF version  Print abstract

Efficacy and safety of gepotidacin versus standard of-care antibiotics for the treatment of uncomplicated urogenital infections in adults and adolescents: a systematic review and meta-analysis
Others Urological Conditions
 1 min.

 Published on 15/05/2026 |  Original article (Full-text)  | Mounika Reddy et al. | Expert Review of Anti-infective Therapy 2026; 24(4): 425-34

Gepotidacin, a novel oral antibacterial targeting bacterial DNA gyrase and topoisomerase IV, exhibits potent activity against Escherichia coli and Neisseria gonorrhoeae resistant strains. This systematic review and meta-analysis assessed the efficacy and safety of gepotidacin compared with standard-of-care...

HTML version PDF version  Print abstract